Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-3512676 + docetaxel
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
PF-3512676 + docetaxel is an investigational combination therapy for cancer, notably non-small cell lung cancer (NSCLC). PF-3512676 is a synthetic oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonist that activates plasmacytoid dendritic cells and B lymphocytes, triggering innate and adaptive antitumor immune responses. Docetaxel is a cytotoxic chemotherapy agent that stabilizes microtubules and inhibits cell division. PF-3512676 was investigated with cytotoxic chemotherapy regimens (including docetaxel and other taxanes) to potentially enhance immune-mediated tumor cell killing. Clinical trials in advanced NSCLC were discontinued due to lack of efficacy and increased toxicity without clinical benefit[1][3][5].
- Other names
- PF-3512676 + docetaxelCpG 7909 + docetaxel
02
Targets
TLR9 (Toll-like receptor 9)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on PF-3512676 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-3512676 + docetaxel.